Home > Cardiology > ESC 2021 > Polypill including aspirin most successful for preventing CVD events

Polypill including aspirin most successful for preventing CVD events

Presented By
Prof. Philip Joseph, McMaster University, Canada
Conference
ESC 2021
Trial
TIPS-3; HOPE-3; Polylran
A meta-analysis of 3 large primary prevention trials revealed that fixed-dose combination treatments are successful to prevent cardiovascular (CV) death, myocardial infarction (MI), stroke, or revascularisation. Benefits are most pronounced in the elderly. About 80% of cardiovascular disease (CVD) events occur in individuals without prior vascular disease. “Therefore, strategies that avoid a high proportion of first CVD events are critical to reducing global CVD burden,” said Prof. Philip Joseph (McMaster University; Hamilton Health Services, Canada) [1]. Fixed-dose combination (FDC) treatment could substantially reduce CVD risk, but more data are needed to quantify efficacy. The so-called polypill in a single formulation usually contains 2+ blood pressure-lowering agents, a statin, and eventually aspirin. In their meta-analysis of long-term, randomised controlled trials (each including >1,000 participants >2 years follow-up), the researchers tested ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on